Xiangrong Zuo

Nov 15, 2024 | genomemedicine.biomedcentral.com | Tongpeng Xu |Tian Tian |Chen Wang |Xiaofeng Chen |Xiangrong Zuo |Hanyu Zhou | +9 more

This was a researcher-initiated, single-arm, open-label, single-center, first-in-human clinical trial (ChiCTR2100046544) designed to evaluate the safety and efficacy of KT032 in patients with mesothelin-expressing advanced solid tumors between August 2021 and February 2024, at the First Affiliated Hospital of Nanjing Medical University. Tumor biopsies were evaluated for mesothelin (MSLN) expression at enrolment, followed by leukapheresis and KT032 manufacture.